SI M006
Alternative Names: SI-M006Latest Information Update: 28 Feb 2023
At a glance
- Originator Sichuan Baili Pharmaceutical
- Developer Sichuan Baili Pharmaceutical; SystImmune
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours; Squamous cell cancer
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for phase-I development in Solid-tumours in USA (Parenteral)
- 28 Feb 2023 No recent reports of development identified for phase-I development in Squamous-cell-cancer in China (Parenteral)
- 21 Jan 2020 Phase-I clinical trials in Solid tumours in USA (Parenteral) (SystImmune Pipeline January 2020) Before Jan 2020